Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7073535 | 0.86 | HSD17B1 (0.40) | BRD4TSHRALOX15MAPTKMT2A | |
| SCHEMBL6414529 | 0.84 | MTNR1A (0.46) | BRD4KMT2A | |
| SCHEMBL6414533 | 0.84 | MTNR1A (0.46) | BRD4KMT2A | |
| SCHEMBL7945190 | 0.82 | ALDH1A1 (0.48) | PDE3BPDE3ATSHRALOX15MAPT | |
| SCHEMBL7076204 | 0.79 | BRD4 (0.39) | BRD4TSHRMAPTKMT2AGAA | |
| SCHEMBL14425118 | 0.78 | MTNR1A (0.57) | — | |
| SCHEMBL6526999 | 0.76 | PDE3B (0.35) | PDE3BPDE3ABRD4TSHRALOX15 | |
| SCHEMBL7075428 | 0.76 | BRD4 (0.42) | PDE3BPDE3AOPRM1BRD4TSHR | |
| SCHEMBL7826091 | 0.75 | PDE3B (0.50) | PDE3BPDE3ATSHRMAPTKMT2A | |
| SCHEMBL7073283 | 0.75 | HSD17B1 (0.47) | OPRM1TSHRALOX15MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | WYETH (US) | 2003-06-12 | — | — | US | disclosed |
| US-6429214-B1 | INHIBITORS OF BONE RESORPTION | WYETH | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | ITGAV, ITGB2, ITGB3 | PDE3B 518/4885PDE3A 700/4885OPRM1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.